Search clinical trials for: Salmeterol/fluticasone propionate or formoterol/budesonide

Total 215 results

University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
Dey

Completed

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
AstraZeneca

Completed

Atlantis Symbicort

Asthma
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Asthma, Allergic

China
AstraZeneca

Completed

Symbicort Onset of Action 1

Asthma
Medical University of Warsaw

Completed

Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma

Asthma | Cough Variant Asthma

Poland
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION)

Asthma

Denmark, United States, Canada, Germany, Sweden, United Kingdom
Hull University Teaching Hospitals NHS Trust

Completed

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
GlaxoSmithKline

Completed

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma

Germany, France
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Brigham and Women's Hospital
Massachusetts General Hospital; Baim Institute for Clinical Research

Terminated

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations (GABLE)

Asthma

United States
AstraZeneca

Completed

Symbicort Onset of Action 2

Asthma
AstraZeneca

Completed

Airway Clearance Study

Chronic Obstructive Pulmonary Disease

United Kingdom, Sweden
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Peking University People's Hospital
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Unknown

Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure

Chronic Obstructive Pulmonary Disease | Chronic Respiratory Failure

China
AstraZeneca

Completed

Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

Asthma

Brazil, France, South Africa, Spain, Vietnam, Germany, Philippines, Malaysia, China, Canada, Argentina, Australia, Mexico, Thailand, Indonesia, Singapore, India
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
AstraZeneca

Completed

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma

Germany
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
Research in Real-Life Ltd
Napp Pharmaceuticals Limited

Completed

A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Asthma

United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Safety of Foradil in Patients With Persistent Asthma

Persistent Asthma

United States
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
Yale University

Completed

Comparison of Nasal Steroids After FESS in CRSwNP

Sinusitis | Nasal Polyps

United States
GlaxoSmithKline

Completed

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Asthma

United States, Russian Federation, Canada, Germany, Peru, Australia, Mexico, Chile, Costa Rica, Spain, Poland, Lithuania, Latvia
GlaxoSmithKline

Completed

Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Asthma

United Kingdom, New Zealand
Mundipharma Korea Ltd

Terminated

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (RECONFFIRM)

Asthma
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
GlaxoSmithKline

Completed

Study Of Asthma In Patients Of African Descent

Asthma

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma

3

Subscribe